PCLAF and coronary atherosclerosis: Furthermore, niacin therapy reduces the risk of cardiovascular diseases and the progression of coronary atherosclerosis by decreasing circulating levels of fibrinogen and increasing of plasminogen-activating factor (PAF) [5].